Devices, digital health, and the technology changing how care is delivered.
U.S.-based Boulevard Bio is paying $20 million upfront to China’s Metis TechBio for the global rights to a trispecific T-cell engager for autoimmune diseases.
The FDA has delayed a decision on the approval of Praxis Precision Medicine’s rare epilepsy prospect by three months. TD Cowen analysts said they “strongly believe FDA bandwidth constraints from last year’s agency downsizing likely contributed to the delay.”
June has seen a slew of executive hires, exits and layoffs across the healthcare industry. For instance, the American Medical Association, CMS and R1 RCM named new executives. There were also layoffs at organizations including ADC Therapeutics, Equip and UPMC. The post Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs appeared first on MedCity News .
Health tech companies made several major funding announcements in June. Here is a list of some of the biggest funding rounds. The post 4 Notable Health Tech Funding Announcements in June appeared first on MedCity News .
Ipsen is acquiring Kartos Therapeutics to get navtemadlin, which has reached Phase 3 testing in the blood cancer myelofibrosis. The Kartos oral small molecule takes a novel approach to restoring the function of p53, a tumor-suppressing protein. The post Ipsen’s $450M Deal Brings Drug That Could Make a Standard Blood Cancer Therapy Better appeared first on MedCity News .
Just two and a half months after buzzing out of stealth with $300 million and five autoimmune programs from Bristol Myers Squibb, busy Beeline Medicines has flown an extra $126.3 million back to its hive.
Edwards Lifesciences is expected to introduce the new device to surgical heart valve customers this year in a “measured, targeted rollout,” one analyst said.
CAR-T cell therapy has flourished since it was first used in 2010, leading to seven approved medicines for different blood cancers. But adapting the powerful technique, which involves engineering a patient’s own T cells to fight cancer, to solid tumors has proven a vexing challenge.
Current AI tools often increase the disruption that radiologists already experience from using non-integrated platforms. The post Radiologists Need AI That Works Where They Work, Not Standalone Software appeared first on MedCity News .
Background Periodic cognitive monitoring for mild cognitive impairment (MCI) is crucial. However, standard assessments like the Montreal Cognitive Assessment (MoCA) require in-person administration due to visual-based items, creating significant accessibility barriers. Objective This study aims to develop and rigorously validate a machine learning model to accurately estimate total MoCA scores using only telephone-based (remote) items and demographic information. Methods Data from three independent MCI cohorts (2022–2024) were used. Data from 2022 to 2023 (N=425) formed the training set; 2024…
J&J is working to expand use of Shockwave’s technology as competition in intravascular lithotripsy builds from companies like Boston Scientific and Stryker.
Sobi’s plan to introduce a challenger to Amgen’s blockbuster gout drug Krystexxa has been put on hold by the FDA.
After scrapping development on its diabetic macular edema treatment avoralstat last month, BioCryst has announced it is shuttering all internal discovery programs to focus on external innovation and partnerships.
As Neuphoria continues to navigate the fallout of its failed social anxiety program, the biotech is mulling an offer from another potential buyer.
Roche may have failed to buy out Illumina back in 2012, but now it’s trying to take up some of the gene sequencing specialist’s market share with its own next-gen platform.
United Therapeutics has been given a premarket approval from the FDA for its LungFX device.
Ipsen is paying $450 million upfront to buy U.S.-based Kartos Therapeutics for a phase 3-stage blood cancer drug designed to improve Jakafi treatment.
Before policymakers, employers, insurers, or taxpayers commit ever-larger sums to the system, an uncomfortable question deserves attention: How much additional capacity does healthcare actually need and what measurable outcomes should society expect in return? The post Healthcare’s Most Avoided Question: “How Much Exactly Do You Need, and What Will America Get in Return?” appeared first on MedCity News .
Cultivating a positive culture is a priority for hospital leaders, but many are making avoidable mistakes. Myra Gregorian, Seattle Children’s chief people and transformation officer, outlined some of these common blunders — such as not involving frontline staff in decision making and assuming that simple communication methods are sufficient. The post 3 Traps Health Systems Fall Into When Trying to Improve Their Culture appeared first on MedCity News .
Alopexx has resuscitated its plans for a public listing as the biotech seeks urgently needed funds to advance a pipeline that includes an infectious disease antibody that was once the focus of a $375 million deal with Sanofi.
A European Medicines Agency committee now recommends withdrawing marketing authorization for Tavneos, an Amgen drug marketed in Europe by a CSL Limited subsidiary. Meanwhile, an FDA proposal to withdraw the drug from the U.S. market is set to go to a hearing. The post EMA: Amgen, Vifor Inflammatory Drug’s Benefits No Longer Outweigh Risks appeared first on MedCity News .
Rural health system Reid Health is using Abridge’s AI-powered documentation tech to reduce burnout among nurses. It appears to be working — after-shift charting is down by up to 45 minutes, and the RN vacancy rate has been cut more than in half, said Misti Foust-Cofield, Reid’s chief nursing officer. The post Documentation Tools Aren’t Just for Doctors: Inside Reid Health’s Deployment of Abridge’s Nurse Tech appeared first on MedCity News .
Aidoc is working on an artificial intelligence feature that would analyze chest X-rays and generate preliminary reports for more than 100 findings.
The acquisition strengthens Agilent’s presence in areas including cancer and infectious disease diagnostic and research markets.